Assignee
XENCOR INC
US·174 granted patents·195 pending applications·4,233 citations·filing 1999–2025
Top patents by PatentIndex Score
369 records- 0199US12466897B2Heterodimeric human IgG1 polypeptides with isoelectric point modificationsXENCOR INC·Filed 2025·Granted Nov 11, 2025·1 cites·1 claims
- 0299US9605084B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Mar 28, 2017·74 cites·16 claims
- 0399US8367805B2Fc variants with altered binding to FcRnXENCOR INC·Filed 2008·Granted Feb 5, 2013·210 cites·3 claims
- 0499US8039592B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2007·Granted Oct 18, 2011·86 cites·19 claims
- 0599US7662925B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2006·Granted Feb 16, 2010·349 cites·15 claims
- 0699US7317091B2Optimized Fc variantsXENCOR INC·Filed 2004·Granted Jan 8, 2008·872 cites·1 claims
- 0799US7276585B2Immunoglobulin variants outside the Fc regionXENCOR INC·Filed 2005·Granted Oct 2, 2007·197 cites·1 claims
- 0898US10793632B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2017·Granted Oct 6, 2020·22 cites·5 claims
- 0998US10584176B2Fc variants with increased affinity for FcγRIIcXENCOR INC·Filed 2018·Granted Mar 10, 2020·21 cites·10 claims
- 1098US10550185B2Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragmentsXENCOR INC·Filed 2017·Granted Feb 4, 2020·29 cites·13 claims
- 1198US10501543B2IL15/IL15Rα heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2017·Granted Dec 10, 2019·13 cites·6 claims
- 1298US10428155B2Trispecific antibodiesXENCOR INC·Filed 2015·Granted Oct 1, 2019·39 cites·5 claims
- 1398US10336818B2Fc variants with altered binding to FcRnXENCOR INC·Filed 2014·Granted Jul 2, 2019·47 cites·5 claims
- 1498US10259887B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2016·Granted Apr 16, 2019·25 cites·25 claims
- 1598US10227410B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Mar 12, 2019·36 cites·27 claims
- 1698US9856327B2Heterodimeric antibodies to CD3 X CD123XENCOR INC·Filed 2016·Granted Jan 2, 2018·72 cites·5 claims
- 1798US9803023B2Fc variants with altered binding to FcRnXENCOR INC·Filed 2015·Granted Oct 31, 2017·62 cites·9 claims
- 1898US9701759B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Jul 11, 2017·48 cites·8 claims
- 1998US9650446B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted May 16, 2017·44 cites·9 claims
- 2098US9051373B2Optimized Fc variantsXENCOR INC·Filed 2013·Granted Jun 9, 2015·40 cites·4 claims
- 2198US8383109B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2012·Granted Feb 26, 2013·40 cites·4 claims
- 2298US8362210B2Antibody variants with enhanced complement activityXENCOR INC·Filed 2011·Granted Jan 29, 2013·47 cites·10 claims
- 2398US7657380B2Methods of generating variant antibodies with increased host string contentXENCOR INC·Filed 2004·Granted Feb 2, 2010·169 cites·47 claims
- 2497US12492253B1Anti-human C5 antibodiesXENCOR INC·Filed 2025·Granted Dec 9, 2025·1 cites·1 claims
- 2597US11591401B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Feb 28, 2023·19 cites·5 claims
- 2697US11472890B2Heterodimeric antibodies that bind ENPP3 and CD3XENCOR INC·Filed 2020·Granted Oct 18, 2022·9 cites·4 claims
- 2797US11225528B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·13 claims
- 2897US10787518B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2017·Granted Sep 29, 2020·15 cites·19 claims
- 2997US10526417B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2015·Granted Jan 7, 2020·27 cites·15 claims
- 3097US10184000B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2016·Granted Jan 22, 2019·20 cites·38 claims
- 3197US9605061B2Antibodies with modified isoelectric pointsXENCOR INC·Filed 2014·Granted Mar 28, 2017·43 cites·7 claims
- 3296US11919958B2Anti-CD28 compositionsXENCOR INC·Filed 2021·Granted Mar 5, 2024·9 cites·16 claims
- 3396US11401348B2Heterodimeric Fc variantsXENCOR INC·Filed 2019·Granted Aug 2, 2022·10 cites·5 claims
- 3496US11358999B2IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2019·Granted Jun 14, 2022·12 cites·2 claims
- 3596US11254727B2CTLA4-Ig immunoadhesinsXENCOR INC·Filed 2021·Granted Feb 22, 2022·2 cites·4 claims
- 3696US10738133B2Heterodimeric proteinsXENCOR INC·Filed 2017·Granted Aug 11, 2020·9 cites·7 claims
- 3796US9353187B2Optimized FC variants and methods for their generationXENCOR INC·Filed 2013·Granted May 31, 2016·21 cites·9 claims
- 3896US8858937B2Optimized Fc variants and methods for their generationXENCOR INC·Filed 2013·Granted Oct 14, 2014·20 cites·9 claims
- 3996US8802823B2Optimized Fc variantsXENCOR INC·Filed 2013·Granted Aug 12, 2014·24 cites·18 claims
- 4096US7315786B2Protein design automation for protein librariesXENCOR INC·Filed 2001·Granted Jan 1, 2008·183 cites·18 claims
- 4196US6403312B1Protein design automatic for protein librariesXENCOR INC·Filed 1999·Granted Jun 11, 2002·321 cites·8 claims
- 4295US12509495B2LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domainsXENCOR INC·Filed 2023·Granted Dec 30, 2025·1 cites·5 claims
- 4395US11919956B2Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3XENCOR INC·Filed 2021·Granted Mar 5, 2024·4 cites·8 claims
- 4495US11655277B2IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2022·Granted May 23, 2023·2 cites·1 claims
- 4595US11623957B2Heterodimeric antibodies that bind CD3 and PSMAXENCOR INC·Filed 2016·Granted Apr 11, 2023·9 cites·28 claims
- 4695US11505595B2TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domainsXENCOR INC·Filed 2019·Granted Nov 22, 2022·9 cites·12 claims
- 4795US11225521B2Heterodimeric antibodies that bind somatostatin receptor 2XENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·23 claims
- 4895US11053316B2Optimized antibody variable regionsXENCOR INC·Filed 2018·Granted Jul 6, 2021·7 cites·6 claims
- 4995US10981992B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2018·Granted Apr 20, 2021·6 cites·6 claims
- 5095US10227411B2Modulation of T cells with bispecific antibodies and FC fusionsXENCOR INC·Filed 2016·Granted Mar 12, 2019·17 cites·7 claims
Showing the top 50 of 369 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →